33 completed, 7 terminated, 2 unknown, 1 active not recruiting. 44 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 44 | Completed 33, Terminated 7, Unknown 2, Active not recruiting 1, Withdrawn 1 |
| Phase 2 | 2 | Completed 1, Terminated 1 |
Follow Choroid Plexus Neoplasms: new trials by email Literature Review of Choroid Plexus Neoplasms trials Research Report on Choroid Plexus Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms ONC206 - Central Nervous System Neoplasms, Glioblastoma | Phase 1 | Active not recruiting | Jazz Pharmaceuticals | 35 | 2020-10-26 | 2026-11-09 |
| Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors palbociclib isethionate, pharmacological study, laboratory biomarker analysis - Childhood Choroid Plexus Tumor, Childhood Ependymoblastoma | Phase 1 | Terminated | Pediatric Brain Tumor Consortium | 35 | 2014-12-08 | 2021-03-02 |
| p28 in Treating Younger Patients With Recurrent or Progressive Central Nervous System Tumors azurin-derived cell-penetrating peptide p28 - Teratoid Tumor, Atypical, Choroid Plexus Neoplasms | Phase 1 | Completed | Pediatric Brain Tumor Consortium | 18 | 2013-08-01 | 2017-08-07 |
| RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma 3-Dimensional Conformal Radiation Therapy, Gamma-Secretase Inhibitor RO4929097, Intensity-Modulated Radiation Therapy - Acoustic Schwannoma, Adult Anaplastic (Malignant) Meningioma | Phase 1 | Completed | National Cancer Institute (NCI) | 22 | 2010-05-01 | 2015-09-29 |
| Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia gamma-secretase/Notch signalling pathway inhibitor RO4929097, diagnostic laboratory biomarker analysis, pharmacological study - Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Choriocarcinoma | Phase 1 | Terminated | National Cancer Institute (NCI) | 129 | 2010-03-01 | 2014-11-05 |
| Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors vorinostat, temozolomide, diagnostic laboratory biomarker analysis - Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Choriocarcinoma | Phase 1 | Completed | National Cancer Institute (NCI) | 27 | 2010-02-01 | 2013-05-03 |
| Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma vorinostat, bortezomib, pharmacological study - Childhood Burkitt Lymphoma, Childhood Central Nervous System Choriocarcinoma | Phase 1 | Completed | National Cancer Institute (NCI) | 20 | 2009-08-01 | 2013-07-02 |
| ABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS Tumors veliparib, temozolomide, pharmacological study - Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Germ Cell Tumor | Phase 1 | Completed | National Cancer Institute (NCI) | 31 | 2009-07-01 | 2014-07-09 |
| Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors carboplatin, dasatinib, etoposide phosphate - Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor | Phase 1 / Phase 2 | Terminated | City of Hope Medical Center | 7 | 2008-09-10 | 2026-11-04 |
| MK0752 in Treating Young Patients With Recurrent or Refractory CNS Cancer MK-0752 - Brain and Central Nervous System Tumors | Phase 1 | Terminated | Pediatric Brain Tumor Consortium | 33 | 2008-07-01 | 2012-03-06 |
| A Feasibility, Dose-Escalation Study Using Intracerebral Microdialysis to Assess the Neuropharmacodynamics of Temsirolimus in Patients With Primary or Metastatic Brain Tumors temsirolimus, pharmacological study, cytokine levels - Brain and Central Nervous System Tumors, Metastatic Cancer | Phase 1 | Completed | City of Hope Medical Center | 12 | 2008-06-01 | 2018-04-17 |
| Enzastaurin in Treating Young Patients With Refractory Primary CNS Tumors enzastaurin hydrochloride - Brain and Central Nervous System Tumors, Neuroblastoma | Phase 1 | Completed | Pediatric Brain Tumor Consortium | 32 | 2007-06-01 | 2012-03-06 |
| Talotrexin in Treating Young Patients With Recurrent Solid Tumors or Leukemia That is Recurrent or Does Not Respond to Treatment talotrexin, chemotherapy - Brain and Central Nervous System Tumors, Leukemia | Phase 1 | Withdrawn | Children's Oncology Group | 2007-02-01 | 2014-08-08 | |
| Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma ispinesib, laboratory biomarker analysis, pharmacological study - Childhood Burkitt Lymphoma, Childhood Central Nervous System Germ Cell Tumor | Phase 1 | Completed | National Cancer Institute (NCI) | 30 | 2006-06-01 | 2013-01-16 |
| Talabostat Combined With Temozolomide or Carboplatin in Treating Young Patients With Relapsed or Refractory Brain Tumors or Other Solid Tumors carboplatin, talabostat mesylate, temozolomide - Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor | Phase 1 | Completed | National Institutes of Health Clinical Center (CC) | 26 | 2005-12-01 | 2012-03-15 |
| Temozolomide, Vincristine, and Irinotecan in Treating Young Patients With Refractory Solid Tumors irinotecan hydrochloride, temozolomide, vincristine sulfate - Brain and Central Nervous System Tumors, Unspecified Childhood Solid Tumor, Protocol Specific | Phase 1 | Completed | Children's Oncology Group | 42 | 2005-10-01 | 2023-10-02 |
| Topotecan in Treating Young Patients With Neoplastic Meningitis Due to Leukemia, Lymphoma, or Solid Tumors topotecan hydrochloride - Brain and Central Nervous System Tumors, Carcinoma of Unknown Primary | Phase 1 | Terminated | Pediatric Brain Tumor Consortium | 19 | 2005-08-01 | 2011-06-30 |
| Positron Emission Tomography Using Fluorine F 18 EF5 to Find Oxygen in Tumor Cells of Patients Who Are Undergoing Surgery or Biopsy for Newly Diagnosed Brain Tumors EF5, conventional surgery, positron emission tomography - Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma | Phase 1 | Terminated | National Cancer Institute (NCI) | 46 | 2005-06-01 | 2013-01-16 |
| Erlotinib Alone or in Combination With Radiation Therapy in Treating Young Patients With Refractory or Relapsed Malignant Brain Tumors or Newly Diagnosed Brain Stem Glioma erlotinib hydrochloride, mutation analysis, polymorphism analysis - Brain and Central Nervous System Tumors | Phase 1 | Unknown | Children's Cancer and Leukaemia Group | 48 | 2005-05-01 | 2013-09-20 |
| VNP40101M in Treating Young Patients With Recurrent, Progressive, or Refractory Primary Brain Tumors laromustine - Brain and Central Nervous System Tumors | Phase 1 | Completed | Pediatric Brain Tumor Consortium | 42 | 2005-02-01 | 2011-06-30 |
Showing 20 of 44. Sign in to see all of them.
Astrocytoma (44) · Medulloblastoma (43) · Oligodendroglioma (37) · Familial ependymoma (31) · Optic Nerve Glioma (31) · Central Nervous System Neoplasms (29) · Meningioma (13) · Rhabdoid Tumor (13) · Glioblastoma (12) · Neuroblastoma (12) · Neuroectodermal Tumors, Primitive (12) · Pinealoma (12) · Burkitt Lymphoma (11) · Ependymoma (11)
Brain Diseases (44) · Central Nervous System Diseases (44) · Cerebral Ventricle Neoplasms (44) · Neoplasms by Histologic Type (44) · Neoplasms by Site (44) · Neoplasms, Germ Cell and Embryonal (44) · Neoplasms, Glandular and Epithelial (44) · Neoplasms, Nerve Tissue (44) · Nervous System Diseases (44) · Nervous System Neoplasms (44) · Neuroectodermal Tumors (43) · Neoplasms, Neuroepithelial (41) · Neoplasms (40) · Glioma (35) · Brain Neoplasms (34)
Temozolomide (9) · Carboplatin (6) · Filgrastim (6) · Peripheral Blood Stem Cell Transplantation (4) · Etoposide (3) · O(6)-benzylguanine (3) · 2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide (2) · Bortezomib (2) · Cyclophosphamide (2) · Granulocyte Colony-Stimulating Factor (2) · Radiotherapy (2) · Vincristine (2) · Vorinostat (2) · etoposide phosphate (2) · 2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole (1)
National Cancer Institute (NCI) (14) · Pediatric Brain Tumor Consortium (9) · National Institutes of Health Clinical Center (CC) (5) · Children's Oncology Group (3) · City of Hope Medical Center (3) · Case Comprehensive Cancer Center (1) · Children's Cancer and Leukaemia Group (1) · Daiichi Sankyo (1) · Duke University (1) · Jazz Pharmaceuticals (1) · Medical College of Wisconsin (1) · Novartis Pharmaceuticals (1) · Roswell Park Cancer Institute (1) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1) · University of Pittsburgh (1)
United States (42) · Canada (5) · Australia (2) · Ireland (1) · United Kingdom (1)
Elizabeth Fox, MD (2) · Jana Portnow, MD (2) · Mark W. Kieran, MD, PhD (2) · Susan M. Blaney, MD (2) · AeRang Kim, MD (1) · Allen R. Chen, MD, PhD, MHS (1) · Amar Gajjar (1) · Antonio Omuro (1) · Barbara Jean Bambach, MD (1) · Bruce H. Cohen, MD (1) · Darren Hargrave, MD (1) · David Van Mater, MD (1) · Denise Adams, MD (1) · Elizabeth Lowe (1) · Harry T. Whelan, MD (1)
PMID 11410496, PMID 16234526, PMID 16533779, PMID 16914576, PMID 17634493, PMID 17941066, PMID 18281544, PMID 18281546, PMID 18470481, PMID 19065567, PMID 19075272, PMID 19430790, PMID 20044751, PMID 20049936, PMID 20460632, PMID 21850464, PMID 23554030, PMID 35417530, PMID 37553297, PMID 9849694
U01CA081457 (9), U01CA097452 (5), P30CA033572 (3), P30CA008748 (1), P30CA043703 (1), U01CA069856 (1)